234 related articles for article (PubMed ID: 21431419)
1. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.
Wood LM; Pan ZK; Guirnalda P; Tsai P; Seavey M; Paterson Y
Cancer Immunol Immunother; 2011 Jul; 60(7):931-42. PubMed ID: 21431419
[TBL] [Abstract][Full Text] [Related]
2. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.
Seavey MM; Maciag PC; Al-Rawi N; Sewell D; Paterson Y
J Immunol; 2009 May; 182(9):5537-46. PubMed ID: 19380802
[TBL] [Abstract][Full Text] [Related]
3. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.
Kim SH; Castro F; Paterson Y; Gravekamp C
Cancer Res; 2009 Jul; 69(14):5860-6. PubMed ID: 19584282
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.
Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y
Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565
[TBL] [Abstract][Full Text] [Related]
5. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R; Dominiecki ME; Jaffee EM; Paterson Y
J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
[TBL] [Abstract][Full Text] [Related]
6. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.
Kim SH; Castro F; Gonzalez D; Maciag PC; Paterson Y; Gravekamp C
Br J Cancer; 2008 Sep; 99(5):741-9. PubMed ID: 18728665
[TBL] [Abstract][Full Text] [Related]
7. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer.
Lee SH; Mizutani N; Mizutani M; Luo Y; Zhou H; Kaplan C; Kim SW; Xiang R; Reisfeld RA
Cancer Immunol Immunother; 2006 Dec; 55(12):1565-74. PubMed ID: 16565828
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
[TBL] [Abstract][Full Text] [Related]
10. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
Singh R; Paterson Y
Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis.
Ghouse SM; Vadrevu SK; Manne S; Reese B; Patel J; Patel B; Silwal A; Lodhi N; Paterson Y; Srivastava SK; Karbowniczek M; Markiewski MM
J Immunol; 2020 Feb; 204(4):990-1000. PubMed ID: 31900334
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Bequet-Romero M; Ayala M; Acevedo BE; RodrÃguez EG; Ocejo OL; Torrens I; Gavilondo JV
Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
[TBL] [Abstract][Full Text] [Related]
13. A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma.
Nguyen HM; Oladejo M; Paulishak W; Wood LM
Cancer Immunol Immunother; 2023 Sep; 72(9):2889-2903. PubMed ID: 36562824
[TBL] [Abstract][Full Text] [Related]
14. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
15. Development of a Listeria monocytogenes based vaccine against prostate cancer.
Shahabi V; Reyes-Reyes M; Wallecha A; Rivera S; Paterson Y; Maciag P
Cancer Immunol Immunother; 2008 Sep; 57(9):1301-13. PubMed ID: 18273616
[TBL] [Abstract][Full Text] [Related]
16. Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth.
Dolinsek T; Markelc B; Sersa G; Coer A; Stimac M; Lavrencak J; Brozic A; Kranjc S; Cemazar M
PLoS One; 2013; 8(3):e58723. PubMed ID: 23593103
[TBL] [Abstract][Full Text] [Related]
17. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
Tsujie M; Uneda S; Tsai H; Seon BK
Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine.
Ren S; Fengyu ; Zuo S; Zhao M; Wang X; Wang X; Chen Y; Wu Z; Ren Z
Vaccine; 2011 Aug; 29(34):5802-11. PubMed ID: 21482223
[TBL] [Abstract][Full Text] [Related]
19. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
20. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
